Hormonal contraception and risk of major adverse cardiovascular events: A nationwide registry study from Finland
*Prospective nationwide cohort with nested case-control; Level 2b (OCEBM).
Citation
Edrees E, Gyllenberg F, Putaala J, Haukka J, Heikinheimo O. Hormonal contraception and risk of major adverse cardiovascular events: A nationwide registry study from Finland. Contraception. 2026;156:111311. doi:10.1016/j.contraception.2025.111311
Background
Earlier studies suggested some hormonal contraceptives may increase blood-clot–related heart and brain events. Because formulations and prescribing practices have changed, updated safety data are needed.
Patients
Women aged 15–49 living in Finland (n=584,236). Excluded: prior heart attack or stroke before follow-up, and several prior cancers.
Intervention
Current use of systemic hormonal contraception, including combined pills containing ethinyl estradiol or estradiol, and progestin-only pills.
Control
Non-use (no redeemed prescription for any hormonal contraception in the prior 360 days).
Outcome
Major adverse cardiovascular events: first hospitalization for heart attack or ischemic stroke.
Follow-up Period
Up to 2 years (2018–2019).
Results
| Outcome | Cases | Incidence per 100,000 person-years |
|---|---|---|
| Major adverse cardiovascular events | 334 | 28.6 |
| Heart attack | 84 | 7.2 |
| Ischemic stroke | 250 | 21.4 |
After adjustment, risk estimates (odds ratios) for major adverse cardiovascular events were not significantly different for combined pills with ethinyl estradiol, combined pills with estradiol, or progestin-only pills versus non-use.
Limitations
Short follow-up and relatively few events limit precision. Smoking and body weight were not available, leaving possible unmeasured differences between users and non-users. Some long-acting methods were not captured in prescription data, and prescription fills do not guarantee actual use.
Funding
Jane and Aatos Erkko Foundation; Primary Care Research Foundation; Helsinki University Hospital.
Clinical Application
Reassure most reproductive-age patients that modern systemic hormonal contraception did not show higher heart attack or ischemic stroke risk when used according to guidelines.
Discussion
Sign in to join the discussion.
In this prospective registry-based cohort with a nested case–control analysis, EE-containing CHC use had an adjusted OR 1.24 (0.78–1.96) for MACE (MI/ischemic stroke) vs nonuse; how do unmeasured confounding (e.g., smoking/BMI), exposure misclassification, and wide CIs shape your confidence and contraceptive counseling/practice change?